To include your compound in the COVID-19 Resource Center, submit it here.

Japan approves Mitsubishi's Canalia for Type II diabetes

Last month, Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) and

Read the full 87 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE